| Name | Title | Contact Details |
|---|
Rénibus Therapeutics® Inc. | A biotech company dedicated to transforming the cardio-renal disease treatment paradigm by focusing on the prevention, treatment, and diagnostic testing of kidney disease.
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
DPT is a contract development and manufacturing organization specializing in semi-solid and liquid dosage forms. Recognized globally for technical expertise and virtually unlimited manufacturing capabilities, DPT is the industry source for fully
Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.
SpaLab is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.